Objectives/hypothesis: To investigate changes in parotid and submandibular gland volumes of patients with head and neck cancer treated with postoperative intensity-modulated radiotherapy (IMRT) or conventional radiotherapy (CRT), and to relate the volume changes to different mean radiation therapy (RT) doses to the parotid and submandibular glands.

Methods: Between May 2007 and May 2008, 82 head and neck cancer patients (oral cavity cancer, 71; oropharynx cancer, 11) were treated with surgery and postoperative RT (IMRT, 40; CRT, 42) at our institution. Every patient underwent four computed tomography (CT) scans: one before RT, one after 3 weeks or at the 15th fraction of RT, one upon completing RT, and one at 2 months after RT; 39 of 82 patients had an additional CT scan at 6 months after RT. A dose-volume histogram was used to evaluate the mean volumes of patients' parotid and submandibular glands and mean RT doses to the glands on every CT scan. Altogether, 241 salivary glands (parotid, 162; submandibular, 79) were analyzed. The volume changes of the glands were evaluated against three levels of mean gland doses: <30 Gy, 30 to 50 Gy, and >50 Gy.

Results: The mean RT doses to spared parotid glands, spared submandibular glands, and irradiated submandibular glands in patients treated with IMRT were 22.21 Gy, 18.26 Gy, and 52.19 Gy, respectively. The mean doses to parotid and submandibular glands in patients treated with CRT were 50.22 Gy and 62.09 Gy, respectively. The average volume loss rates in parotid glands after 3 weeks of RT, at the end of RT, and 2 months after RT versus before RT were 20.01%, 26.93%, and 27.21%, respectively. The average volume loss rates in submandibular glands after 3 weeks of RT, at the end of RT, and 2 months after RT versus before RT was 11.49%, 16.76%, and 16.29%, respectively. Parotid and submandibular glands did not continue to shrink after completing RT. We observed more volume loss during RT in the parotid glands than in the submandibular glands. The average rates of volume loss during the first 3 weeks of RT (20.01% and 11.49%, respectively) were larger than in the last 3 weeks of RT (8.57% and 6.0%, respectively). No significant differences were observed in the mean volumes of both parotid and submandibular glands between the end of RT, 2 months post-RT, and 6 months post-RT (P > .05). Volume loss at higher doses (>30 Gy) to the glands was significantly larger than at low doses (<30 Gy; P < .001).

Conclusions: The parotid and submandibular glands shrunk during RT, but the parotid glands shrunk more than the submandibular glands. These gland volume reductions correlated significantly with the mean dose to the irradiated glands; the spared glands showed few changes.

Download full-text PDF

Source
http://dx.doi.org/10.1002/lary.20601DOI Listing

Publication Analysis

Top Keywords

submandibular glands
36
parotid submandibular
28
volume loss
20
glands
16
volume changes
12
submandibular
12
glands patients
12
head neck
12
neck cancer
12
parotid glands
12

Similar Publications

Objectives: The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) categorizes fine needle aspiration and cytology (FNAC) results into 6 tiers and assigns a risk of malignancy (ROM) to each category. Its utility in submandibular gland lesions remains unclear. Our article aims to study (1) the utility of the MSRSGC in classifying FNAC of submandibular gland masses, (2) describe the demographics and incidence of submandibular gland malignancy in our population, and (3) analyze the accuracy of FNAC in diagnosis of benign and malignant submandibular gland tumors.

View Article and Find Full Text PDF

Ancient schwannoma of the submandibular gland.

BMJ Case Rep

January 2025

Division of Plastic and Reconstructive Surgery, Department of Surgery, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand

Schwannomas, benign tumours derived from Schwann cells, exhibit slow growth rates and are commonly found extracranially in the head, neck and extremities. However, intraoral and salivary gland schwannomas are less frequent. Ancient schwannomas, characterised by histological degenerative changes, represent a rare variant.

View Article and Find Full Text PDF

Methotrexate (MTX) is an antimetabolite drug utilized for managing a variety of cancers and autoinflammatory conditions. MTX may trigger detrimental effects in mout, h tissues, including salivary gland impairment. Bosentan (BOS), a drug that blocks endothelin receptors, has strengthened antioxidant, anti-inflammatory, and anti-apoptotic properties.

View Article and Find Full Text PDF

Background: Currently, a majority of institution-specific automatic MRI-based contouring algorithms are trained, tested, and validated on one contrast weighting (i.e., T2-weighted), however their actual performance within this contrast weighting (i.

View Article and Find Full Text PDF

Objective: To establish a submandibular gland imaging reporting and data system (SI-RADS) and explore its value in diagnosing submandibular gland (SMG) tumors.

Study Design: Patients with primary SMG tumors who underwent enhanced computed tomography (CT) scanning and surgical intervention at Peking University Hospital of Stomatology (2013-2022) were retrospectively included. The imaging data were assessed for acquisition of the relevant imaging features, including lesion boundary, shape, enhancement, calcification, lymph node, and adjacent tissue involvement, and vascular invasion.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!